American Research Corporation

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)4 trials
• Liver cirrhosis1 trial
• Primary biliary cholangitis1 trial

Phase

• Phase 23 trials
• Phase 32 trials

Status

• Recruiting4 trials
• Active, not recruiting1 trial

Lead sponsor

• Regeneron Pharmaceuticals3 trials
• Eli Lilly and Company1 trial
• Ipsen1 trial

Running trials

• Recruiting

  Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

  NCT07527910· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Carmen Landaverde (principal investigator)

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

  Contact: Ipsen Clinical Study Enquiries

• Active, not recruiting

  A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Phase 2· Regeneron Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Liver cirrhosis1 recruiting
• Primary biliary cholangitis1 recruiting